Sign in
Taking people in South KoreaNo phase

Checks fatty liver risk in people with type 2 diabetes in routine care

Follows adults with type 2 diabetes treated with dapagliflozin and pioglitazone.

Key facts

Who runs it
Boryung Pharmaceutical Co., Ltd
Where
Andong and Seoul, South KoreaSee the 2 sites
Trial code
Registry title
A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
Status
Recruiting
People taking part
10,000 people, planned
Started
30 Sept 2024
Expected to end
Mar 2027
Type of study
Observational
Record updated
18 October 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes who are scheduled to start a fixed-dose combination of dapagliflozin/pioglitazone. It studies the risk of fatty liver disease (NAFLD) and how useful this combination is.

Age
19 years and older
Sex
All sexes can join.
Disease stage
Type 2 diabetes.
Earlier treatment
People must not have taken the fixed-dose combination of dapagliflozin/pioglitazone before the start of the study (visit 1).

Main reasons for not taking part

  • Has a history of taking the fixed-dose combination of dapagliflozin/pioglitazone at visit 1
  • Is expected to need insulin during the study

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Among patients with type 2 diabetes, those who are scheduled to administer a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1)
  • Those who voluntarily signed a written personal information collection and usage agreement after listening to an explanation about the objective and method, etc. of this clinical study

Who cannot take part

  • Those who have a history of taking a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1)
  • Those who are expected to need insulin prescription during the study period

Where in South Korea

  • Andong HospitalAndong, South KoreaContact: Joong-kyung SungTaking people
  • Konkuk University Medical CenterSeoul, South KoreaContact: Kee-ho SongNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone combination therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multi-center, Prospective, Cohort Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
Plain-language title
Checks fatty liver risk in people with type 2 diabetes in routine careGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
18 October 2024